Pasithea Therapeutics Corp. (KTTA): R&D Expense
$7.98M
Year ended 2025-12-31
$10.73M
Trailing 12 months to 2026-06-30
+44.1%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.98M | +10.9% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $7.20M | -11.1% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $8.10M | +203.9% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $2.67M | n/a | 2024-03-29, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $7.98M | +10.9% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $107.0K | -82.0% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $22.84M | +180.2% |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $24.61M | +29.2% |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $77.00M | -33.8% |
| Scynexis Inc (SCYX) | 2025-12-31 | $22.28M | -15.6% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $19.16M | -60.2% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $20.20M | -24.3% |
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $24.77M | -38.8% |
Compare KTTA, PRPH, PVLA, DMAC side by side · Screen every company in Pharmaceutical Preparations ↗